ESMO 2022 | Adjuvant and neoadjuvant chemo-IO for UK patients with NSCLC

Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, Maidstone, UK, touches on unanswered questions regarding the use of neoadjuvant and adjuvant chemo-immunotherapy for patients in the United Kingdom with non-small cell lung cancer (NSCLC), including treatment duration as well as eligibility for immunotherapy. Dr Shah discusses CheckMate-816 (NCT02998528) and NADIM (NCT03081689) which may provide more answers on the role of neoadjuvant chemo-IO in NSCLC. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.